This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): CP-690550, CP-690, 550, tasocitinib, tofacitinib, Zeruyantsu (Japan), Jaquinus (Russia), Xeljanz XR extended-release
Description: Tofacitinib (CP-690550) is a moderately selective Janus-Kinase-3 (JAK3) inhibitor. Additional pharmacokinetic data have shown that at clinical concentrations Tofacitinib actually functions to inhibit Jak1 and Jak2 in addition to Jak3. The Jaks are required for cytokine signaling that is essential for T-cell development, proliferation or differentiation, making them necessary for the initiation of innate and adaptive immune responses.
Deal Structure: Revenue splits for this drug are BioMedTracker estimates.
Pfizer and Takeda
In February 2011, Pfizer and Takeda signed a new co-promotion agreement in Japan for tofacitinib. The co-promotion agreement between Takeda and Pfizer for Tofacitinib is for RA and certain other potential indications in Japan. Pfizer will receive a milestone payment from Takeda at the launch of tofacitinib and Takeda will receive a percentage of sales (based on certain conditions specified in the contract) as a co-promotion fee from Pfizer. Contractual details were not disclosed.
In August 2016, Pfizer and Takeda announced that they have concluded a co-promotion agreement for the rheumatoid arthritis (RA) drugs XELJANZ (generic name: tofacitinib citrate) and ENBREL (generic name: etanercept), the co-promotion of which will be continued by both companies while the marketing will be continued by Takeda.
Partners: Takeda Pharmaceutical Company Ltd
Xeljanz/Xeljanz XR News
Additional information available to subscribers only: